iXensor Co., Ltd. (6734.TWO) Stock

About iXensor Co., Ltd.

iXensor Co., Ltd. operates a cutting-edge technological platform that transforms standard smartphones into sophisticated in vitro diagnostic (IVD) instruments, advancing the field of connected healthcare. This innovation is powered by their proprietary PixoTest technology, which intelligently leverages a smartphone's integrated lighting and image sensing modules to accurately detect and interpret color-change reactions on immunoassay or colorimetric test strips. The company's diverse product portfolio addresses various health management needs: Chronic Diseases: Solutions like the PixoTest Blood Glucose Monitoring System and PixoTest POCT System assist in managing long-term conditions. Women's Health: The Eveline Smart Fertility System and Eveline Care Telehealth Platform provide tools for fertility tracking and remote care. Infectious Diseases: Offerings such as the PixoTest COVID-19 Rapid Antigen Test facilitate rapid detection and management. Additionally, iXensor provides supporting digital infrastructure, including the PixoHealth Pass Admin app and its corresponding web portal. Established in Taipei, Taiwan, in 2012, the company is a pioneer in mobile-driven diagnostic solutions.

iXensor Co., Ltd. is led by CEO Yanyu Chen, employs 50 people, headquartered in Taipei, TW, publicly traded since 2019.

over the past 52 weeks the stock has ranged between $4.70 and $18.50, and currently trades 71.9% below its 52-week high.

Official website: www.ixensor.com

iXensor Co., Ltd. (6734.TWO) — frequently asked questions